Shares of Vectura Group PLC (LON:VEC) have received a consensus recommendation of “Buy” from the ten brokerages that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is GBX 174.86 ($2.42).

Several equities analysts have recently weighed in on VEC shares. Panmure Gordon reissued a “buy” rating and set a GBX 150 ($2.07) price target on shares of Vectura Group in a report on Thursday, November 9th. Numis Securities lowered their price target on Vectura Group from GBX 205 ($2.83) to GBX 170 ($2.35) and set a “buy” rating on the stock in a report on Thursday, November 9th. Shore Capital reissued a “buy” rating on shares of Vectura Group in a report on Thursday, November 9th. Peel Hunt reissued a “hold” rating and set a GBX 160 ($2.21) price target on shares of Vectura Group in a report on Thursday, January 4th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of Vectura Group in a report on Thursday, November 16th.

Vectura Group (LON:VEC) traded down GBX 3.25 ($0.04) during midday trading on Tuesday, hitting GBX 78.10 ($1.08). The stock had a trading volume of 2,691,291 shares, compared to its average volume of 4,980,000. Vectura Group has a 12-month low of GBX 77.30 ($1.07) and a 12-month high of GBX 166.97 ($2.31).

COPYRIGHT VIOLATION WARNING: This piece was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://theolympiareport.com/2018/02/13/vectura-group-plc-vec-receives-consensus-rating-of-buy-from-brokerages.html.

Vectura Group Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.